AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36241352 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted therapy
Number of subjects: 90
Study 36241352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32964282 — intervention group
Group type: EXPERIMENTAL
Intervention: Midface lift plus facial lipofilling
Number of subjects: 56
Study 32964282 — intervention group
Group type: COMPARATOR
Intervention: Midface lift only
Number of subjects: 56
Study 32127283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DEX (2 μg/kg)
Number of subjects: 60
Study 32127283 — intervention group
Group type: COMPARATOR
Intervention: Intranasal DEX-KET (2 μg/kg DEX + 1 mg/kg KET)
Number of subjects: 60
Study 33200456 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal relational role analysis (IRRA)
Number of subjects: 8
Study 33199806 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Electrolyzed Water (NEW) 58 ppm
Number of subjects: 3
Study 33199806 — intervention group
Group type: EXPERIMENTAL
Intervention: NaClO 35 ppm
Number of subjects: 3
Study 33199806 — intervention group
Group type: COMPARATOR
Intervention: Saline Solution (SS)
Number of subjects: 3
Study 33199806 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Electrolyzed Water (NEW)
Number of subjects: 3
Study 33916940 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlantic diet intervention group
Number of subjects: 720
Study 33916940 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual lifestyle)
Number of subjects: 720
Study 32541299 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen vaginal cream (applied for at least 5 weeks preoperatively and continued twice-weekly through 12 months postoperatively)
Number of subjects: 197
Study 32541299 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 197
Study 32541299 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 197
Study 33933853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg once daily
Number of subjects: 459
Study 36342475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg once daily
Number of subjects: 5438
Study 36342475 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100mg once daily
Number of subjects: 5438
Study 33793290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 83
Study 33793290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 33793290 — intervention group
Group type: COMPARATOR
Intervention: Control beverages
Number of subjects: 83
Study 32447856 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Baihui (GV20) and Shuigou (GV26) points in addition to routine western medicine treatment.
Number of subjects: 70
Study 32447856 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine treatment (control group).
Number of subjects: 70
Study 34757701 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceived stress (PSS-10 scores)
Number of subjects: 247
Study 34757701 — intervention group
Group type: EXPERIMENTAL
Intervention: Single marital status, high-risk pregnancy, IL-2, TNF-α
Number of subjects: 247
Study 34757701 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 247
Study 32812785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea gravel
Number of subjects: 0
Study 32812785 — intervention group
Group type: EXPERIMENTAL
Intervention: Beech wood chips
Number of subjects: 0
Study 32812785 — intervention group
Group type: EXPERIMENTAL
Intervention: Spruce wood chips
Number of subjects: 0
Study 32812785 — intervention group
Group type: COMPARATOR
Intervention: Soil
Number of subjects: 0
Study 33004398 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR) therapy
Number of subjects: 20
Study 33550553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosulfan 0.75 ppb/day
Number of subjects: 0
Study 33550553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosulfan 1.0 ppb/day
Number of subjects: 0
Study 33550553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosulfan 1.5 ppb/day
Number of subjects: 0
Study 33550553 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to endosulfan)
Number of subjects: 0
Study 36123633 — intervention group
Group type: EXPERIMENTAL
Intervention: Preamble (improved question wording)
Number of subjects: 1400
Study 36123633 — intervention group
Group type: COMPARATOR
Intervention: Standard weight question
Number of subjects: 1400
Study 36123633 — intervention group
Group type: COMPARATOR
Intervention: Weight-specific question
Number of subjects: 1400
Study 36123633 — intervention group
Group type: COMPARATOR
Intervention: No preamble (control condition)
Number of subjects: 1400
Study 34144591 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICK TAPE
Number of subjects: 20
Study 34144591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dye Taping
Number of subjects: 20
Study 32911462 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA-guided PCI
Number of subjects: 60
Study 32911462 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 60
Study 35019237 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone-impregnated packing
Number of subjects: 22
Study 35019237 — intervention group
Group type: COMPARATOR
Intervention: Normal saline-soaked packing (Control)
Number of subjects: 22
Study 33724614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen–ozone therapy (O2–O3)
Number of subjects: 20
Study 34129127 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week adaptive biofeedback (ABF) training
Number of subjects: 42
Study 34129127 — intervention group
Group type: COMPARATOR
Intervention: fixed biofeedback (FBF) training
Number of subjects: 42
Study 34338469 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of primary breast cancer (26 mastectomy and 19 breast conserving surgery)
Number of subjects: 45
Study 32725861 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Led Therapist Supervised Articulation Therapy (PLAT)
Number of subjects: 44
Study 32725861 — intervention group
Group type: COMPARATOR
Intervention: Routine speech therapy intervention
Number of subjects: 44
Study 35901382 — intervention group
Group type: COMPARATOR
Intervention: Baseline pain
Number of subjects: 688
Study 35901382 — intervention group
Group type: COMPARATOR
Intervention: Incident pain
Number of subjects: 688
Study 35901382 — intervention group
Group type: COMPARATOR
Intervention: Pain persistence
Number of subjects: 688
Study 33569757 — intervention group
Group type: EXPERIMENTAL
Intervention: One implant in the midline of the mandibular symphysis (GA group)
Number of subjects: 18
Study 33569757 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implants in the lower canine region (GB group)
Number of subjects: 18
Study 33569757 — intervention group
Group type: COMPARATOR
Intervention: Two implants (GB group)
Number of subjects: 18
Study 33569757 — intervention group
Group type: COMPARATOR
Intervention: One implant (GA group)
Number of subjects: 18
Study 33475536 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromobilization (NM)
Number of subjects: 80
Study 33475536 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 80
Study 33810773 — intervention group
Group type: EXPERIMENTAL
Intervention: Online motivational interviewing training program (Group 1)
Number of subjects: 44
Study 33810773 — intervention group
Group type: EXPERIMENTAL
Intervention: Online motivational interviewing training program and live booster session (Group 2)
Number of subjects: 44
Study 32013830 — intervention group
Group type: EXPERIMENTAL
Intervention: FCSM (fermented cottonseed meal)
Number of subjects: 180
Study 32013830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ct‐Sc CSM (fermented cottonseed meal with C. tropicalis plus S. Cerevisae)
Number of subjects: 180
Study 32013830 — intervention group
Group type: COMPARATOR
Intervention: Unfermented CSM (control group)
Number of subjects: 180
Study 35314068 — intervention group
Group type: EXPERIMENTAL
Intervention: coDiagnostiX
Number of subjects: 24
Study 35314068 — intervention group
Group type: COMPARATOR
Intervention: Implant Studio
Number of subjects: 24
Study 32169149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam combined with tigecycline
Number of subjects: 114
Study 32169149 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone-sulbactam sodium alone
Number of subjects: 114
Study 33789549 — intervention group
Group type: EXPERIMENTAL
Intervention: Health intervention
Number of subjects: 1056
Study 32880954 — intervention group
Group type: EXPERIMENTAL
Intervention: SDoH V-codes
Number of subjects: 5313965
Study 32880954 — intervention group
Group type: COMPARATOR
Intervention: Medical diagnoses without SDoH V-codes
Number of subjects: 5313965
Study 32880954 — intervention group
Group type: COMPARATOR
Intervention: Combined SDoH and medical diagnoses codes
Number of subjects: 5313965
Study 32880954 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of 40 SDoH codes
Number of subjects: 5313965
Study 2011315466 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acid (EFA), fibrin sealant, and Unna's boot (Group 2)
Number of subjects: 24
Study 2011315466 — intervention group
Group type: COMPARATOR
Intervention: Essential fatty acid (EFA) and Unna's boot (Group 1)
Number of subjects: 24
Study 35643253 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) plus standard of care (SOC)
Number of subjects: 99
Study 35643253 — intervention group
Group type: COMPARATOR
Intervention: Palliative standard of care (SOC)
Number of subjects: 99
Study 34037821 — intervention group
Group type: EXPERIMENTAL
Intervention: Shake containing 30g of cashew nuts and 15g of Brazil nuts
Number of subjects: 15
Study 34037821 — intervention group
Group type: COMPARATOR
Intervention: Shake absent of nuts (matched for energy and macronutrient content)
Number of subjects: 15
Study 34037821 — intervention group
Group type: EXPERIMENTAL
Intervention: Shake containing nuts
Number of subjects: 15
Study 34037821 — intervention group
Group type: COMPARATOR
Intervention: Shake absent of nuts
Number of subjects: 15
Study 33318380 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid users (cases)
Number of subjects: 436
Study 33753954 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling with a client-centered approach based on the GATHER principles
Number of subjects: 72
Study 33753954 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling (Control)
Number of subjects: 72
Study 32578353 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 134
Study 32578353 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 134
Study 34214989 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training, 30-Hz frequency, 3 series of four 45-s exercises with a 45-s rest, total of 12 sessions (2 sessions per week for 6 weeks)
Number of subjects: 16
Study 34214989 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 16
Study 33057953 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS) 2 mg
Number of subjects: 22
Study 33057953 — intervention group
Group type: COMPARATOR
Intervention: ENTOCORT EC 9 mg
Number of subjects: 22
Study 33057953 — intervention group
Group type: EXPERIMENTAL
Intervention: BOS 2 mg
Number of subjects: 22
Study 33057953 — intervention group
Group type: EXPERIMENTAL
Intervention: BOS 2 mg and ENTOCORT EC 9 mg
Number of subjects: 22
Study 36182772 — intervention group
Group type: EXPERIMENTAL
Intervention: active-tDCS
Number of subjects: 50
Study 33610485 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (InGaAs diode laser, 980nm, 100mW, 10J per tooth)
Number of subjects: 22
Study 33610485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no photobiomodulation)
Number of subjects: 22
Study 32917160 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Star Toilet campaign intervention
Number of subjects: 2483
Study 32917160 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2483
Study 35899970 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardiac rehabilitation (sitting, standing, walking exercises, endurance training)
Number of subjects: 87
Study 35899970 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 87
Study 35899970 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardiac rehabilitation
Number of subjects: 87
Study 35899970 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardiac rehabilitation (improvement in physical function)
Number of subjects: 87
Study 34511330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplant levels of circulating CLEC4C protein
Number of subjects: 219
Study 34511330 — intervention group
Group type: EXPERIMENTAL
Intervention: CLEC4C alone
Number of subjects: 219
Study 34511330 — intervention group
Group type: EXPERIMENTAL
Intervention: CLEC4C in combination with clinical covariates from the multivariable model
Number of subjects: 219
Study 34511330 — intervention group
Group type: COMPARATOR
Intervention: RADIAL score
Number of subjects: 219
Study 36151758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 36151758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33583293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour Treating Fields (TTFields) delivered via scalp; specific dosage and duration not mentioned.
Number of subjects: 0
Study 33583293 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; outcomes related to control not available.
Number of subjects: 0
Study 32471808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine treatment
Number of subjects: 29
Study 32471808 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 29
Study 35215772 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive RT-PCR group (2292 participants)
Number of subjects: 2998
Study 35215772 — intervention group
Group type: COMPARATOR
Intervention: Negative RT-PCR group (706 participants)
Number of subjects: 2998
Study 34257646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernosal sparing technique with minimal corporal dilatation after intracavernosal injection of Alprostadil
Number of subjects: 33
Study 34257646 — intervention group
Group type: COMPARATOR
Intervention: Conventional implantation with serial vigorous dilatations
Number of subjects: 33
Study 34257646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernosal sparing technique
Number of subjects: 33
Study 36108657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks)
Number of subjects: 50
Study 36108657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks) plus SBRT (24 Gy in three fractions at week 2)
Number of subjects: 50
Study 36108657 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI-naive patients receiving nivolumab and ipilimumab
Number of subjects: 50
Study 36108657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous ICI exposure receiving nivolumab and ipilimumab
Number of subjects: 50
Study 36108657 — intervention group
Group type: COMPARATOR
Intervention: Combined nivolumab and ipilimumab
Number of subjects: 50
Study 36108657 — intervention group
Group type: COMPARATOR
Intervention: Treatment-related adverse events
Number of subjects: 50
Study 33176877 — intervention group
Group type: EXPERIMENTAL
Intervention: Common earmuffs
Number of subjects: 15
Study 33176877 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed molded earplugs
Number of subjects: 15
Study 33176877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing protection devices (HPDs)
Number of subjects: 15
Study 36213954 — intervention group
Group type: EXPERIMENTAL
Intervention: Wise Intervention (WI)
Number of subjects: 1085
Study 36213954 — intervention group
Group type: COMPARATOR
Intervention: Anti-stress control intervention
Number of subjects: 1085
Study 35652136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation technique
Number of subjects: 100
Study 35652136 — intervention group
Group type: COMPARATOR
Intervention: Magill forceps technique
Number of subjects: 100
Study 35652136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study 32500740 — intervention group
Group type: EXPERIMENTAL
Intervention: Naked condition
Number of subjects: 51
Study 32500740 — intervention group
Group type: COMPARATOR
Intervention: Clothed condition (control)
Number of subjects: 51
Study 32990680 — intervention group
Group type: EXPERIMENTAL
Intervention: PDX-derived organoid (PXO) models grown under WNT-free culture conditions
Number of subjects: 10
Study 32990680 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycome analysis of PDX and PXO models
Number of subjects: 10
Study 32990680 — intervention group
Group type: EXPERIMENTAL
Intervention: Secreted biomarker discovery pipeline using media supernatant of organoid cultures
Number of subjects: 10
Study 35967525 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic PDCI with omentectomy (Group A)
Number of subjects: 41
Study 35967525 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic PDCI without omentectomy (Group B)
Number of subjects: 41
Study 35967525 — intervention group
Group type: COMPARATOR
Intervention: Open surgical PDCI (Group C)
Number of subjects: 41
Study 35967525 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic PDCI with omentectomy (Group A) in patients with previously failed catheter insertion
Number of subjects: 41
Study 35967525 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic PDCI without omentectomy (Group B) in patients with previously failed catheter insertion
Number of subjects: 41
Study 35500422 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane plus Epidural (IE group, n = 16)
Number of subjects: 36
Study 35500422 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (I group, n = 20)
Number of subjects: 36
Study 33894554 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity (AMP) treatment (n = 16)
Number of subjects: 29
Study 33894554 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) control (n = 13)
Number of subjects: 29
Study 35727053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1175
Study 35727053 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1175
Study 35727053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1-negative/NLR ≥4)
Number of subjects: 1175
Study 35727053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (excluding EGFR/ALK-positive patients)
Number of subjects: 1175
Study 35727053 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood tumor mutation burden (cutoff, 16 mut/Mb)
Number of subjects: 1175
Study 33497870 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vitamin with mineral supplement (MV, n = 10)
Number of subjects: 21
Study 33497870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, n = 11)
Number of subjects: 21
Study 32096246 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-stable collagen matrix (VCMX)
Number of subjects: 20
Study 32096246 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous subepithelial connective tissue graft (SCTG)
Number of subjects: 20
Study 35606818 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting-STAIR (P‐STAIR) - 23 sessions
Number of subjects: 220
Study 35606818 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling - 23 sessions
Number of subjects: 220
Study 34671996 — intervention group
Group type: EXPERIMENTAL
Intervention: Namodenoson 25 mg b.d.
Number of subjects: 60
Study 34671996 — intervention group
Group type: EXPERIMENTAL
Intervention: Namodenoson 12.5 mg b.d.
Number of subjects: 60
Study 34671996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32364754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapies identified through EHRs
Number of subjects: 622
Study 36385592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentadent Professional® Chlorhexidine 0.05% with vitamin C (ChxC)
Number of subjects: 32
Study 36385592 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol Alito Sicuro® (SnF2)
Number of subjects: 32
Study 36385592 — intervention group
Group type: EXPERIMENTAL
Intervention: CB12® (ZnChx)
Number of subjects: 32
Study 36385592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PbO)
Number of subjects: 32
Study 33410589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursed-lip breathing with number counting (PLB with NC)
Number of subjects: 110
Study 33410589 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical care
Number of subjects: 110
Study 33410589 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PLB with NC vs Conventional medical care
Number of subjects: 110
Study 32458450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oro‐Pharyngeal Administration of Mother's Milk (OPAMM) - 0.2 mL prior to each gavage feeding for 24 hours
Number of subjects: 40
Study 32458450 — intervention group
Group type: COMPARATOR
Intervention: Regular gavage feeding practice
Number of subjects: 40
Study 35526605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg oral)
Number of subjects: 45
Study 35526605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 32429969 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Pulmonary Hypertension Exercise Rehabilitation (SPHERe)
Number of subjects: 352
Study 32429969 — intervention group
Group type: COMPARATOR
Intervention: Best practice usual care
Number of subjects: 352
Study 36417156 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT2206
Number of subjects: 270
Study 36417156 — intervention group
Group type: COMPARATOR
Intervention: ustekinumab (European Union)
Number of subjects: 270
Study 36417156 — intervention group
Group type: COMPARATOR
Intervention: ustekinumab (USA)
Number of subjects: 270
Study 33541836 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut smoothie (48 g walnuts)
Number of subjects: 10
Study 33541836 — intervention group
Group type: COMPARATOR
Intervention: Placebo smoothie (macronutrient-matched without nuts)
Number of subjects: 10